RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...
Dr. Reddy's Laboratories Ltd. 500124 shares advanced 2.39% to 1,303.00 Indian rupees Wednesday, on what proved to be an ...
Discover the Dr Reddys Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent ...
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
Dr. Reddy's' US sales continued to struggle due to inventory adjustments and pricing pressures on key products, Citi said.
Out of the 40 analysts that track Dr. Reddy's, 13 of them have a 'Buy' recommendation, while 16 of them have a 'Sell' call.
Systematix upgraded the stock rating to 'hold' and hiked target price to Rs 1,414 apiece, while Dolat Capital upgraded rating ...
Dr. Reddy’s (DRRD) Q2FY25 EBITDA was largely in line with our estimate. The base business margins and US sales ex of ...
Dr. Reddy’s Laboratories Ltd ( (RDY)) has released its Q2 earnings. Here is a breakdown of the information Dr. Reddy’s Laboratories Ltd presented to its investors. Dr. Reddy’s Laboratories Ltd., a ...
Dr. Reddy’s Laboratories’ (DRL) Q2FY25 performance, adjusted for acquisition-related expenses (INR 561mn) and impairment ...
Dr Reddy's Laboratories Ltd. reported its Q2 FY25 results, with a notable revenue increase of 16.5%, reaching Rs 8,016.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback